Dr. Khawaja Baig, MD

PEER-REVIEWED PUBLICATIONS

1. Activation of vasodepressor reflexes by inotropic catecholamines. Karnad DR, Narula DD, Kulkarni SD, Anand AN, Tilve GH. N Engl J Med 1990; 322: 1531

2. Health Care in India. Johari P, Narula D, Gandhi N, Patel V. Br Med J 1993; 306: 1341

3. Percutaneous balloon dilatation of cor triatriatum sinister. Kerkar P, Vora A, Kulkarni H, Narula D, Goyal V, Dalvi B. Am Heart J 1996; 132(4): 888-91

4. Spontaneous coronary artery dissection in a young man with inferior wall myocardial infarction. Shah C, Narula D, Kulkarni H, Dalvi B. Am Heart J 1996; 132(3): 696-8

5. Early intrinsic deflection – a marker for successful radiofrequency ablation of overt accessory pathways. Lokhandwala YY, Smeets JLRM, Steld Bv, Narula D, Stockman D, Wellens HJJ. Ind Heart J 1996; 48: 138-144

6. Percutaneous stent implantation in an adult with left pulmonary artery stenosis and absent right pulmonary artery. Dalvi BV, Vora AM, Narula D, Kulkarni H. Eur Heart J 1997; 18(4): 700-1

7. Coil occlusion of a residual ductus arteriosus remaining after implantation of a buttoned device. Dalvi B, Vora A, Narula D, Goyal V, Ramakanthan R, Kulkarni H. Cathet Cardiovasc Diagn 1996; 39(1): 52-4

8. Percutaneous balloon occlusion of post-infarction ventricular septal defect. Vajifdar B, Vora A, Narula D, Kulkarni H. Ind Heart J 1996; 48(4): 407-8

9. Transcatheter radiofrequency ablation of tachyarrythmias. Vora A, Iyer R, Goyal V, Lokhandwala Y, Sathe S, Narula D, Dalvi B, Kulkarni H. J Assoc Phys India 1997; 45:349-55

10. New technique using temporary balloon occlusion for transcatheter closure of patent ductus arteriosus with Gianturco coils. Dalvi B, Goyal V, Narula D, Kulkarni H, Ramakantan R. Cathet Cardiovasc Diagn 1997; 41(1): 62-70

11. Risk factors for development of atrial fibrillation. Ehlert FA, Narula DD, Steinberg JS. In: “Atrial Fibrillation After Cardiac Surgery”, edited by Steinberg JS, Kluwer Academic Publishers, Norwell, MA 1999, pp. 51-80

12. Atrial fibrillation after noncardiac surgery. Narula DD, Steinberg JS. In: “Atrial Fibrillation After Cardiac Surgery”, edited by Steinberg JS, Kluwer Academic Publishers, Norwell, MA 1999, pp. 141-164

13. Diagnosis of Amiodarone Pulmonary Toxicity with High-Resolution Computerized Tomographic Scan. Siniakowicz RM, Narula D, Suster B, Steinberg JS. J Cardiovasc Electrophysiol 2001; 12: 431-6

14. The effect of head-upright tilt-table testing for vasovagal syncope on P-wave duration. Haider J, Kalus JS, White CM, Narula DD, Guertin DC, Caron MF, Kluger J. J Electrocardiol 2002; 35: 303-6

15. QT dispersion and viable myocardium in patients with prior myocardial infarction and severe left ventricular dysfunction. Li VH, Dorbala S, Narula D, Depuey G, Steinberg JS. Ann Noninvasive Electrocardiol 2002; 7: 53-9

16. Differences between QT and RR intervals in digital and digitized paper electrocardiograms: contribution of the printer, scanner, and digitization process. Hingorani P, Karnad Dr, Panicker GK, Deshmukh S, Kothari S, Narula DD. J Electrocardiol 2008; 41:370-5

17. Z-score for benchmarking reader competence in a central ECG laboratory. Panicker GK, Karnad DR, Joshi R, Shetty S, Vyas N, Kothari S, Narula DD. Ann Noninvasive Electrocardiol 2009; 14:19-25

18. Intra- and interreader variability in QT interval measurement by tangent and threshold methods in a central electrocardiogram laboratory. Panicker GK, Karnad DR, Natekar M, Kothari S, Narula DD, Lokhandwala YY. J Electrocardiol 2009; 42:348-52

19. Effect of Number of Replicate Electrocardiograms Recorded at Each Time Point in a Thorough QT Study on Sample Size and Study Cost. Natekar M, Hingorani P, Gupta P, Karnad DR, Kothari S, de Vries M, ZumBrunnen T, Narula D. Journal of Clinical Pharmacology 2011;51:908-14

20. Automated QT interval measurements in 12-lead digital Holter ECGs: A comparison of ECGs sampled at 180 Hz and 1000 Hz. Panicker GK, Salvi V, Karnad DR, Macfarlane P, Clark E, Ramasamy A, Kothari S, Narula D. Computing in Cardiology 2010;37:761-764

21. Difference in automated QT interval measurements in Holter electrocardiograms recorded at sampling rates of 180 and 1000 Hz: effects of up-/down-sampling of the digital electrocardiogram signal. Panicker GK, Salvi V, Karnad D, Ramasamy A, Kothari S, Narula D. Journal of Electrocardiology 2011– J Electrocardiol. 44. 10.1016/j.jelectrocard.2010.12.098.

22. Limb Lead Interchange in Thorough QT/QTc Studies. Salvi V, Karnad DR, Panicker GK, Kothari S, Hingorani P, Natekar M, Mahajan V, Narula D. Journal of Clinical Pharmacology 2011; 51(10):1468-73

23. Comparison of five methods of QT interval measurements on ECGs from a thorough QT/QTc study: Effect on assay sensitivity and categorical outliers. Salvi V, Karnad DR, Panicker GK, Natekar M, Hingorani P, Kerkar V, Ramasamy A, de Vries M, ZumBrunnen T, Kothari S, Narula D. Journal of Electrocardiology 2011; 44(2):96-104

24. Choice of an alternative lead for QT interval measurement in serial ECGs when Lead II is not suitable for analysis. Salvi V, Karnad DR, Kerkar V, Panicker GK, Manohar D, Natekar M, Kothari S, Narula D, Lokhandwala Y..Indian Heart Journal 2012; 64(6):535-40

25. Morphological abnormalities in baseline ECGs in healthy normal volunteers participating in phase I studies.Hingorani P, Natekar M, Deshmukh S, Karnad DR, Kothari S, Narula D, Lokhandwala Y. Indian J Med Res. 2012; 135:322-30

26. QTc interval and its variability in patients with schizophrenia and healthy subjects: implications for a thorough QT study. Hingorani P, Karnad DR, Natekar M, Kothari S, Narula D, Lokhandwala Y. Int J Neuropsychopharmacol. 2012;15:1535-40

27. Baseline and new-onset morphologic ECG abnormalities in healthy volunteers in phase I studies receiving placebo: changes over a 6-week follow-up period. Hingorani P, Karnad DR, Natekar M, Kothari S, Narula D. Journal of Clinical Pharmacology 2014 ;54:776-84

28. Sudden Death in Patients With Coronary Heart Disease Without Severe Systolic Dysfunction. Chatterjee NA, Moorthy MV, Pester J, Schaecter A, Panicker GK, Narula D, Lee DC, Goldberger JJ, Kadish A, Cook NR, Albert CM, for the PRE-DETERMINE Study Group JAMA Cardiol. 2018;3(7):591–600. doi:10.1001/jamacardio.2018.1049

29. Estimating Myocardial Infarction Size with a Simple Electrocardiographic Marker Score. Lee DC, Albert CM, Narula D, Kadish AH, Panicker GK, Wu E, Schaechter A, Pester J, Chatterjee NA, Cook NR, Goldberger JJ. J Am Heart Assoc. 2020; 9:e014205. doi: 10.1161/JAHA.119.014205

30. Simple electrocardiographic measures improve sudden arrhythmic death prediction in coronary disease. Chatterjee NA, Tikkanen JT, Panicker GK, Narula D, Lee DC, Kentta T, Junttila JM, Cook NR, Kadish A , Goldberger JJ, Huikuri HV, Albert CM, for the PREDETERMINE Investigators. European Heart Journal 2020; 41: 1988–1999, https://doi.org/10.1093/eurheartj/ehaa177

31. Validation of electrocardiographic criteria for identifying left ventricular dysfunction in patients with previous myocardial infarction. Panicker GK, Narula D, Albert C, Lee DC Kothari S, Goldberge JJ, Cook NR, Schaechter A, Kim E, Moorthy MV, Pester J, Chatterjee N, Kadish A, Karnad D. Annals of Noninvasive Electrocardiology 2020. https://doi.org/10.1111/anec.12812

32. A Rare Case Report of Flecainide-Induced Left Bundle Branch Block (LBBB) and Transient Cardiomyopathy. Chauhan S, Morris D, Bhatnagar M,Shah P, Narula D. Cureus 2023 15(4): e37184. DOI 10.7759/cureus.37184

DISSERTATION

For M.D. (General Medicine)
1. A study of Creatinine clearance in Iron deficiency and its’ correction by oral Iron. Narula D, Medhekar TP. Dissertation accepted by the University of Bombay for the award of the degree of M.D. (Medicine), 1992

For D.M. (Cardiology)
2. Transcatheter closure of the Patent Ductus Arteriosus. Narula D, Kulkarni HL. Dissertation accepted by the University of Bombay for the award of the degree of D.M. (Cardiology), 1995

ABSTRACTS (US/EUROPE)

1. Prolonged QT Dispersion Correlates with Appropriate Implantable Cardioverter-Defibrillator Therapy. Narula DD, Wali AU, Vloka ME, Menon V, Steinberg JS. Circulation 1997; 96:I-715

2. Actuarial Survival of CPI Epicardial and Endocardial Defibrillation and Rate Sensing Leads. Narula DD, Steinberg JS, Ehlert FA, Vloka ME, Novak BJ. Circulation 1997; 96:I-694

3. Relationship of QT Dispersion to Mode of Onset of Spontaneous Ventricular Tachycardia in Patients with Implantable Defibrillators. Narula DD, Kaddaha RM, Wali AU, Vloka ME, Lewis R, Steinberg JS. PACE 1998; 21(no. 4 pt. II): 965

4. Electrophysiology Study Characteristics: Correlation with Cardiac Death and Defibrillator Shocks in the Multicenter Automated Defibrillator Implantation Trial. Narula DD, Steinberg JS, Ehlert FA, Vloka ME, Zareba W, for the MADIT investigators. J Am Coll Cardiol 1998; 31(suppl. A): 159A

5. Do Specialists Make a Difference in the Management of Unexplained Syncope? Vloka ME, Sharma A, Narula DD, Ehlert FA, Steinberg JS. J Am Coll Cardiol 1998; 31 (suppl. A): 363A

6. Age Dependent Atrial Activation Delay: Observations Using the P-Wave Signal Averaged Electrocardiogram. Vloka ME, Sadurski R, Narula DD, Menon V, Ehlert FA, Steinberg JS. J Am Coll Cardiol 1998; 31 (suppl. A): 47A

7. Use of QT dispersion for risk stratification after acute myocardial infarction is hampered by high day to day variability. Vloka ME, Wali AU, Narula DD, Ehlert FA, Steinberg JS. Circulation 1998; 98:I-81A

8. Is there a gender bias in selection of dual chamber and rate responsive pacemakers? Narula DD, Jaber WA, Widmer AJ, Ehlert FA, Vloka ME, Steinberg JS. J Am Coll Cardiol 1999; 33:154A

9. Poor correlation of automated and manual QT dispersion measurements in patients and normal subjects. Vloka ME, Babaev A, Ehlert FA, Narula DD, Steinberg JS. J Am Coll Cardiol 1999; 33:350A

10. Atrial defibrillation using the conventional implantable defibrillator. Kaddaha R, Narula DD, Fefer F, Ehlert FA, Steinberg JS. J Am Coll Cardiol 1999; 33:146A

11. Atrial fibrillation after minimally invasive bypass surgery is not less frequent than after CABG. Sutander A, Tamis JE, Narula D, Gemayel CY, Vloka ME, Steinberg JS. PACE 1999; 22:719

12. Is there any value to pre-ICD electrophysiologic study for patients with ventricular tachyarrhythmias? Vloka ME, Sutander A, Kaddaha RM, Babaev A, Narula DD, Steinberg JS. Circulation 1999; 100:I-571

13. Variations in selection of dual chamber and rate responsive pacemakers: influence of geographic region and physician gender. Narula DD, Jaber WA, Vloka ME, Kim JS, Larsen MD, Kaddaha RM, Ehlert FA, Steinberg JS. J Am Coll Cardiol 2000; 35:141A

14. Adjusted pacemaker implant rates are lower in women than men at all ages – is gender bias at work? Narula DD, Jaber WA, Vloka ME, Kim JS, Larsen MD, Sutander A, Ehlert FA, Steinberg JS. J Am Coll Cardiol 2000; 35:142A

15. Assessing reader variability in a core ECG laboratory. Panicker GK, Karnad DR, Joshi R, Bhoir H, Kothari S, Narula D. Presented at the Drug Information Association Cardiac Safety Conference, Berlin, December 2006

16. Comparison of measurement of the QT and RR intervals between digital electrocardiograms and paper electrocardiograms that are scanned and digitized. Hingorani P, Karnad DR, Panicker GK, Deshmukh S, Kothari S, Narula D. Presented at the Drug Information Association Cardiac Safety Conference, Berlin, December 2006

17. Optimum number of replicates of ECGs in a thorough QT study. Natekar M, Hingorani P, Gupta P, Karnad DR, Kothari S, deVries M, ZumBrunnen T, Narula D. Presented at the Drug Information Association conference on QT and Arrhythmia issues in Drug Development, Washington DC, April 2007

18. Frequency and accuracy of detection of limb lead misplacement in thorough QT studies. Salvi S, Panicker GR, Hingorani P, Mahajan V, Bhoir H, Karnad DR, Kothari S, Narula D. Presented at the Drug Information Association Cardiac Safety Conference, Prague, December 2007

19. Evaluation of intra- and inter observer variability in a core ECG laboratory. Narula D. Presented at IIR Meeting January 2008
20. Prevalence of morphologic abnormalities in healthy normal volunteers on placebo participating in phase I studies. Hingorani P, Natekar M, Deshmukh S, Karnad DR, Kerkar V, Kaurani P, Kothari S, Narula D. Presented at the Drug Information Association conference on QT and Arrhythmia issues in Drug Development, Bethesda, April 2008

21. Do subjects in a positive QT study respond similarly to moxifloxacin and two doses of study drug? Panicker GK, Natekar M, Karnad DR, Kothari S, Narula D. Presented at the Drug Information Association conference on QT and Arrhythmia issues in Drug Development, Bethesda, April 2008

22. Subjects in a positive thorough QT study respond similarly to moxifloxacin and two doses of study drug: is this a pharmacokinetic or a pharmacodynamic response? Panicker GK, Kerkar V, Natekar M, Karnad DR, Kothari S, Narula D. Presented at the American College of Pharmacology 38th Annual Meeting, San Antonio, September 2009

23. Automated QT interval measurements in 12-lead digital Holter ECGs: A comparison of ECGs sampled at 180 Hz and 1000 Hz. Panicker GK, Salvi V, Karnad DR, Macfarlane P, Clark E, Ramasamy A, Kothari S, Narula D. Presented at Drug Information Association (DIA) ‘QT and arrhythmia issues in drug development’, Bethesda. April 2010

24. Frequency and accuracy of detection of limb lead interchange in thorough QT studies. Salvi V, Panicker GK, Karnad DR, Hingorani P, Kothari S, Narula D. Presented at Drug Information Association (DIA) ‘QT and arrhythmia issues in drug development’, Bethesda. April 2010

25. Difference in automated QT interval measurements in Holter ECGs recorded at sampling rates of 180Hz and 1000Hz: Effects of up-/down-sampling of the digital ECG signal. Panicker GK, Salvi V, Karnad DR, Ramasamy A, Kothari S, Narula D. Presented at 37th International Congress on Electrocardiology, Lund, Sweden. June 3-5 2010

26. Comparison of subjects with QTc values exceeding pre-specified upper limits in a thorough QT (TQT) study using five different methods of QT interval measurement. Salvi V, Panicker GK, Hingorani P, Ramasamy A, Natekar M, Karnad DR, Kothari S, Narula D. Presented at 37th International Congress on Electrocardiology, Lund, Sweden. June 3-5 2010

27. Electrocardiographic markers of myocardial infarction size, transmural extent, and extent of nonviable myocardium – comparison to CMR. Lee DC, Albert C, Narula D, Kadish A, Schaechter A, Wu E, Goldberger J. Journal of Cardiovascular Magnetic Resonance 2016 . 18. P78. 10.1186/1532-429X-18-S1-P78.

ABSTRACTS (INDIA/CHINA)

1. Balloon Dilatation of Modified Blalock-Taussig Shunts. Narula D, Kerkar P, Vora A, Gupta S, Banker D, Nabar A, Shah C, Kulkarni H. Ind Heart J 1994; 46: 220

2. Transcatheter treatment of Coronary Arterial Fistulae. Banker D, Vora A, Kerkar P, Narula D, Ramakanthan R, Kulkarni H, Mathew S. Ind Heart J 1994; 46: 220

3. Transcatheter Closure of Atrial Septal Defect and Patent Ductus Arteriosus: Initial Experience. Kerkar P, Kulkarni H, Vora A, Gupta S, Banker D, Narula D, Ramakanthan R, Shah C. Ind Heart J 1994; 46: 211

4. Radiofrequency Catheter Ablation for Tachyarrythmias: an initial experience. Sathe S, Vora A, Lokhandwala Y, Kerkar P, Narula D, Nabar A, Banker D, Kulkarni H. Ind Heart J 1994; 46: 243

5. Percutaneous Balloon Mitral Valvuloplasty in Mitral Restenosis. Gupta S, Kerkar P, Lokhandwala Y, Vora A, Shah C, Narula D, Gupta S, Kulkarni H. Ind Heart J 1994; 46:199

6. Magnesium and Acute Myocardial Infarction- a Late Potentials Study. Gupta S, Gupta S, Pandit RB, Kerkar P, Nabar A, Kulkarni H, Shah C, Narula D. Ind Heart J 1994; 46: 263

7. Use of temporary balloon occlusion to improve results of transcatheter coil closure of patent ductus arteriosus. Narula D, Dalvi B, Ramakantan R, Goyal V, Kulkarni H, Kerkar P, Vora A, Lokhandwala Y. Ind Heart J 1996; 48

8. Radiofrequency ablation of accessory pathways. Vora A, Sathe S, Lokhandwala Y, Narula D, Vajifdar B, Goyal V, Dalvi B, Kulkarni H. Ind Heart J 1995; 47:582

9. Radiofrequency catheter ablation for idiopathic ventricular tachycardia. Vora A, Nabar A, Narula D, Lokhandwala Y, Banker D, Sathe S, Shah C, Iyer R Ind Heart J 1995; 47:649

10. Electrophysiologic properties of the AV node after radiofrequency catheter ablation of slow pathway for AV nodal reentrant tachycardia. Sathe S, Lokhandwala Y, Vora A, Iyer R, Narula D, Nabar A, Vajifdar B, Goyal V, Kulkarni H. Ind Heart J 1995; 47:621

11. Emergency balloon valvuloplasty in patients of mitral stenosis presenting with cardiac arrest, cardiogenic shock or unresponsive pulmonary edema. Banker D, Lokhandwala Y, Dalvi B, Vora A, Kerkar P, Shah C, Narula D, Kulkarni H. Ind Heart J 1995; 47:584

12. Aneurysms of the sinuses of Valsalva: a morphologic study. Nabar A, Iyer R, Vora A, Narula D, Banker D, Shah C, Dalvi B, Kulkarni H. Ind Heart J 1995; 47:570

13. Echocardiography guided balloon atrial septostomy. Shah P, Narula D, Nabar A, Goyal V, Vora A, Iyer R, Dalvi B. Ind Heart J 1995; 47:604

14. Balloon Dilatation of cor triatriatum sinister. Shah C, Kerkar P, Dalvi B, Vora A, Narula D, Goyal V, Agaskar R, Kulkarni H. Ind Heart J 1995; 47:604

15. Correlation of duct size on colour flow and on aortography. Dalvi B, Narula D, Goyal V, Vora A, Kerkar P, Shah C, Kulkarni H. Ind Heart J 1995; 47:570

16. Non Coronary use of stents. Dalvi B, Vora A, Ramakanthan R, Bandekar V, Narula D, Nabar A, Shah P, Kulkarni H. Ind Heart J 1995; 47:570

17. Results of patent ductus arteriosus closure using the buttoned device. Kulkarni H, Narula D, Kerkar P, Lokhandwala Y, Vora A, Dalvi B, Sideris EB. Ind Heart J 1995; 47:580

18. Results of ASD closure using the buttoned device. Kulkarni H, Kerkar P, Lokhandwala Y, Vora A, Narula D, Fulwani M, Gupta S. Ind Heart J 1995; 47:582

19. Transcatheter retrieval of therapeutic occlusion devices. Nabar A, Vora A, Kerkar P, Lokhandwala Y, Dalvi B, Narula D, Kulkarni H. Ind Heart J 1995; 47:582

20. Radiofrequency ablation for ectopic atrial tachycardia. Vajifdar B, Narula D, Lokhandwala Y, Vora A, Shah C, Sathe S, Kulkarni HL. Ind Heart J 1996; 48:491

21. Interventional cardiac catheterisation in neonates and infants. Dalvi BV, Shah P, Narula D, Vajifdar B, Kulkarni S, Iyer R, Kerkar P. Ind Heart J 1996; 48:477

22. Intermediate term follow-up after slow pathway radiofrequency ablation for AV nodal reentrant tachycardia. Shah P, Iyer R, Narula D, Vora A, Sathe S, Lokhandwala Y, Kulkarni HL. Ind Heart J 1996; 48:494

23. Radiofrequency ablation of atypical AV nodal reentrant tachycardia. Kulkarni HL, Iyer R, Narula D, Lokhandwala Y, Vora A, Shah C, Nabar A. Ind Heart J 1996; 48:494

24. Intermediate followup of transcatheter coil closure of patent ductus arteriosus. Narula D, Goyal V, Vajifdar B, Kulkarni S, Kerkar P, Dalvi BV. Ind Heart J 1996; 48:494

25. Balloon pulmonary valvotomy in tetralogy of Fallot – initial results. Fulwani M, Narula D, Kulkarni S, Kerkar P, Nabar A, Vajifdar B, Dalvi BV. Ind Heart J 1996; 48:542

26. Is there a prethrombotic state in left atrial blood in rheumatic mitral stenosis? Nabar A, Narula D, Rodriguez C, Soren D, Vora A, Dalvi BV, Kulkarni HL, Ghosh K, Mohanty D. Ind Heart J 1996; 48:552

27. Wide QRS Complex: Is JTc better than QTc? Lanjevar A, Pathak V, Hemani D, Udeshi P, Salvi S, Narula D, Lokhandwala Y. Ind Heart J 2004; (56(5):528

28. Are there any gender differences in corrected QT interval (Bazett’s and Fridericia) in children between 6 to 14 years of age? Lanjewar P, Pathak V, Hemani D, Salvi S, Narula D, Lokhandwala Y. Ind Heart J 2004; 56(5):534

29. Comparison of 12-lead Holter and digital ECG for assessment of cardiac toxicity in drug trials. Pathak V, Narula D, Hemani D, Salvi S, Borkar S, Lanjewar P, Lokhandwala Y. Ind Heart J 2004; 56(5):529

30. Effect of study design on variability of the QT interval. Hemani D, Narula D, Salvi S, Borkar S, Pathak V, Nayak A, Lokhandwala Y. Ind Heart J 2004; 56(5):530

31. Effect of changes in heart rate on the corrected QT intervals calculated using Bazett’s and Fridericia’s formulae. Karnad D, Shetty S, Salvi S, Vyas N, Kothari S, Narula D, Lokhandwala Y. Ind Heart J Sept-Oct, 2005;57:(5).

32. Do electrocardiography characteristics predict variability in QT measurements in clinical trials? Shetty S, Khan M, Salvi S, Karnad DR, Kothari S, Narula D, Lokhandwala YY. Ind Heart J 2005; 57(5):493

33. Are physiological loads suitable for non-pharmacologic control in thorough QT/QTc study? Sahashi K, Ozaki M, Fujita T, Otani Y, Narula D, Desai D, Kumagai Y. Presented at International Pharmacological Conference, Beijing, China, July 2006.

34. Comparison of machine readings of QT and QTc intervals with manual readings. Deshmukh SR, Joshi R, Shetty S, Kothari S, Narula D, Lokhandwala YY, Karnad DR. Ind Heart J 2006; 58:488

35. Comparison of QT measurement by threshold method and tangent method. Panicker GK, Karnad DR, Joshi R, Kothari S, Narula D, Lokhandwala YY. Ind Heart J 2006;58:488

36. Comparison of Bazett, Fridericia, Framingham, population specific and individual QTc correction formulae. Hingorani P, Natekar MR, Kothari S, Narula D, Lokhandwala YY, Karnad DR. Ind Heart J 2006; 58:487

37. Comparison of QTc interval in diabetics with and without neuropathy and healthy normal volunteers. Salvi S, Hingorani P, Mahajan V, Bhoir H, Karnad DR, Kothari S, Narula D, Lokhandwala YY. Ind Heart J 2007; 59:418

38. Supraventricular arrhythmias in patients with Parkinson’s disease and healthy controls. Panicker GR, Salvi V, Kaurani P, Karnad DR, Kothari S, Narula D, Lokhandwala YY. Ind Heart J 2008; 60:247

39. Sinus arrhythmia in diabetes with and without peripheral neuropathy and in normal healthy subjects. Hingorani P, Satra A, Natekar M, Karnad DR, Kaurani P, Godse NA, Kothari S, Narula D, Lokhandwala YY. Ind Heart J 2008; 60:256

40. Prevalence of morphological abnormalities in healthy subjects participating in clinical trials. Hingorani P, Natekar M, Deshmukh S, Karnad DR, Kothari S, Narula D, Lokhandwala YY. Ind Heart J 2008; 60:361

41. Prevalence of ectopic complexes and arrhythmias on 24-hour Holter in healthy normal volunteers. Hingorani P, Natekar M, Kaurani P, Karnad DR, Kerkar P, Kothari S, Narula D, Lokhandwala YY. Ind Heart J 2008; 60:229

42. Influence of T wave morphology on variability in QT measurements. Deshmukh S, Karnad DR, Natekar M, Atre D, Sonawane R, More N, Panicker GK, Kothari S, Narula D, Lokhandwala YY. Ind Heart J 2008; 60:236

43. Impact of position of LL electrode on QTc interval in 12-lead Holter ECGs in normal healthy subjects. Salvi S, Karnad DR, Panicker GR, Mitesh R, Kothari S, Narula D. Presented at Global Cardiac Safety Conference. Mumbai, March 2008

44. QTc Interval and its variability in schizophrenic patients and healthy subjects. Hingorani P, Natekar M, Karnad DR, Kothari S, Narula D, Lokhandwala YY. Ind Heart J 2009; 61:129

45. Which lead in a 12-lead ECG has a QT interval closest to that in Lead II? Salvi V, Karnad DR, Kerkar V, Panicker GK, Natekar M, Kothari S, Lokhandwala Y, Narula D. Ind Heart J 2010; 61:

46. A study of QTc interval in healthy subjects with early repolarization. Panicker GK, Manohar D, Salvi V, Karnad DR, Kothari S, Narula D, Lokhandwala Y. Ind Heart J 2010; 61:

47. Prevalence of morphologic abnormalities in healthy normal volunteers on placebo participating in Phase I studies. Hingorani PV, Karnad DR, Natekar MR, Kothari S, Narula D, Lokhandwala YY. Presented at 65th Annual Conference of Cardiological Society of India (CSI), Bangalore, India, 5th – 8th December 2013.

Medical School: Nova Southeastern University College of Osteopathic Medicine

Internal Medicine Residency: Cleveland Clinic Florida

Cardiovascular Disease Fellowship: Cleveland Clinic Florida

Interventional Cardiology Fellowship: University of Massachusetts Baystate Medical Center

Dr. Akhtar graduated from Allama Iqbal Medical College, Lahore, Pakistan. He then continued his education at centers of academic excellence. His residency in Internal Medicine was at Baylor College of Medicine in Houston. He completed his three year Cardiology fellowship at University of Texas, Health Science Center in partnership with Texas Heart Institute in Houston. He then trained in the subspecialty of Interventional Cardiology at Baylor University Medical Center, Dallas. He had the fortunate experience of being mentored by physicians that are considered leaders in the field of cardiology.

Dr. Akhtar is Board Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology. He is a Fellow of American College of Cardiology and a Fellow of the Society for Cardiovascular Angiography and Intervention.  In the rapidly advancing and evolving field of Interventional Cardiology he always stays abreast with cutting edge procedures, devices and drug therapy used in the treatment of heart disease.

Dr. Narula has over a hundred publications and presentations, focused on cardiovascular disease and cardiac electrophysiology, in top medical journals. He has expertise in electrocardiography, syncope, atrial fibrillation, and cardiac safety of pharmaceuticals in development.

He received his Bachelor of Science in Computer Science at the University of Michigan before achieving his Master’s degree in Basic Medical Sciences from Wayne State University School of Medicine. He then went on to study here in Nevada at the Touro University and completed his Doctor of Osteopathic Medicine. Dr. Prasad completed his internal medicine residency at Valley Hospital Medical Center in Las Vegas before moving on to his cardiology fellowship in Pontiac, Michigan at McLaren Oakland Hospital, where he was chief fellow.

Experience/excellence

Dr. Prasad began his medical career as an invasive cardiologist in Michigan. After returning to Nevada, he continued to practice and teach in Las Vegas before joining Prime Cardiology of Nevada. Dr. Prasad is a professional member of several medical associations, including the American College of Cardiology, American Society of Nuclear Cardiology, American College of Osteopathic Internists, American Osteopathic Association and Nevada Osteopathic Medical Association.

In August 2020, Dr. Narula was the first doctor in Las Vegas to successfully implant a pacemaker lead to directly pace the left bundle branch. This is a cutting-edge procedure that offers help to patients with weak hearts and congestive heart failure to improve heart function and quality of life.

Dr. Narula moved to Las Vegas in 2005 and has worked to deliver the best quality care to his patients. He has performed over 8000 cardiac procedures with a high level of quality and with excellent outcomes. He has brought several cutting-edge technologies to Las Vegas by his involvement in clinical research.These include the treatment of heart failure with vagal nerve or carotid body stimulators. He performed the first treatment of atrial fibrillation with cryoablation in Nevada and established this program at Mountainview Hospital. He has been recognized as an innovator in bringing advanced technology to Las Vegas and is well versed with robotic navigation for ablation. Because of his efforts, Las Vegas patients had access to the latest MRI-compatible defibrillators well before patients in many surrounding states.

Dr. Narula states that he is very fortunate to have been trained in laser lead extraction by Dr. Navratil who, in his opinion, is one of the best in the world. In fact, most of the physicians performing lead extraction in Las Vegas were either trained by Dr. Navratil or by one of his trainees

Dr. Navratil has taught at the University of Nevada, Reno as a clinical assistant professor of medicine. He now has teaching appointments as an associate professor of medicine at Touro University in Henderson.

Dr. Prasad also has research experience in studies related to chronic kidney disease and coronary artery disease.

1. Correlation of Highly Sensitive Troponin to Coronary Artery Disease McLaren Oakland Hospital, Pontiac, MI
2. Correlate the results of highly sensitive troponins to the diagnosis of coronary artery disease via invasive and noninvasive imaging modalities
3. Investigate the accuracy of highly sensitive troponins in diagnosing coronary artery disease
4. Provide recommendations for community hospitals on how to interpret newly adopted high-sensitivity troponin values Chronic Kidney Disease Research Initiative Valley Hospital Medical Center, Las Vegas, NV

Dr. Prasad is a professional member of several medical associations.

1. American College of Cardiology American Society of Nuclear Cardiology American College of Osteopathic Internists American Osteopathic Association Nevada Osteopathic Medical Association

Dr. Narula has been recognized by his colleagues as an outstanding physician in the community. He has served on the Cardiac Safety Research Consortium, a collaboration between Duke University and the FDA, to advance safety of pharmaceuticals in development. He has served on the Council of the American College of Cardiology Nevada Chapter. He was awarded the Healthcare Headliners Award for his contribution to advancing clinical research in Las Vegas and the AAG Award for being the first physician in the Western United States to implant a MRI-compatible defibrillator. He has been voted multiple times by his colleagues to be a top doctor of Las Vegas.

Dr. Navratil has been voted one of the Best Doctors in America from 2003-2017 and Best Doctor by Desert Companion from 2015-2018

Dr. David Navratil received his Bachelor of Science from St. Norbert College in Wisconsin. He then went to the University of Wisconsin-Madison for his Doctor of Medicine. He completed his first internal medicine residency at Keesler Air Force Base in Biloxi, Mississippi and his cardiology fellowship at Lackland Air Force Base in Texas. He completed an electrophysiology fellowship at Sequoia Hospital District in Redwood City, California. During this time, he also completed 500 hours in a nuclear medicine preceptorship at Lackland Air Force Base.

Experience/excellence

Dr. Navratil began his practice as a cardiologist/electrophysiologist and was the Director of Electrophysiology at Wilford Hall USAF Medical Center. After relocating to Nevada, he continued his practice with the Heart Institute of Nevada, Nevada Heart Care, Nevada Cardiovascular Arrythmia Associates, Cardiovascular Consultants of Nevada, and DaVita Healthcare Parners. He is now continuing his practice at Prime Cardiology of Nevada. He has special interests in treatment of cardiac arrythmias, cardiac ablation, removal of pacemakers and defibrillator systems and pharmacologic treatment of cardiac arrythmia.

Dr. Shaheen Chowdhry graduated from Dow University of Health Sciences in 1990. Dow University, established in 1945 in Karachi, ranks third in medical universities in Pakistan.

Dr. Chowdhry immigrated to the United States in 1992 and completed her internal medicine training in 3 years at the University of Missouri-Kansas City. Additionally, affiliation with Saint Luke’s Health System’s cardiology program and strong cardiology mentorship increased her love for the practice. After completing a 3-year cardiology fellowship program, she moved to Las Vegas to grow her practice and has been here for 21 years.

After working with several medical groups in the city and acquiring extensive experience in the industry, she has decided to move her practice to Prime Cardiology of Nevada. Her primary goal continues to be to provide quality care in cardiology.

Experience/Excellence

Dr. Chowdhry is also involved with organizations outside of her work including the Association of Physicians of Pakistani descent of North America. The Las Vegas chapter of APPNA elected her twice as president and once as secretary. Philanthropically, she is very passionate about helping underprivileged youth, especially girls, receive an education. She volunteers with Developments in Literacy-Pakistan to help combat this issue, which is so close to her heart. Additionally, she locally mentors’ children of refugee families.

Dr. Prasad additionally provides teaching services at several facilities throughout the valley. He has participated as a clinical preceptor for third- and fourth-year medical students at Touro University. He provides inpatient consult services with teaching rounds at the University of Nevada Las Vegas School of Medicine. Lastly, he provides monthly cardiology lectures to fellows, residents and medical students at Valley Hospital in their Internal Medicine Residency Program.

Dr. Santosh Rané received his Bachelor of Medicine and Bachelor of Surgery at the University of Mumbai. After migrating to the United States in 2000, he participated in a state-of-the-art biodefense basic science project at the Fels Institute for Cancer Research and Molecular Biology at Temple University. He then continued to pursue clinical medicine during a transitional year residency at Jefferson University Hospital before finishing an internal medical residency at the Western Michigan University.

Experience/excellence

Post-residency, Dr. Rane worked as an internal medicine hospitalist for five years at the Carilion Clinic in Roanoke, Virginia. He later moved to Shady Grove Medical Center  in Rockville, Maryland. With a strong background in internal medicine, he then finished a cardiovascular medicine fellowship at the Saint Vincent Hospital with several clinical rotations at Harvard Medical School associated hospitals.

From there, Dr. Rane decided to pursue his long-time passion in the field of Cardiac Electrophysiology. He completed a fellowship in this field at the pioneering University of Washington Medical Center in Seattle, Washington.

After some diverse experience in both basic and clinical science, Dr. Rane relocated to Las Vegas and started a cardiovascular medicine and cardiac electrophysiology practice with HealthCare Partners. Here he participated in teaching responsibilities and clinical work. In 2018, Dr. Rane performed the first ablation for Atrial Fibrillation with an in-catheter camera-based laser balloon in the state of Nevada.

Dr. Rane then moved his practice to Prime Cardiology of Nevada to pursue his passion of providing quality care to patients requiring cardiovascular and cardiac electrophysiological care in Las Vegas.

Dr. Cordero has participated in many research projects and been published in several textbooks and journals. He has experience and expertise in cardiovascular diseases, interventional cardiology and nuclear cardiology.

Citations:

1. SVG Protection In a Distal Embolic Protection Randomized Trial (SPIDER)
2. TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program (ARRIVE)
3. Safety and Efficacy of DX-9065 in patients with non-ST elevation acute coronary syndromes (XANADU ACS Study)
4. Randomized Trial to Assess TAXUS Paclitaxel-Eluting Stents in High Risk De Novo Coronary Lesions (TAXUS V)
5. Phase II Safety Study of Systemic Nanoparticle Paclitaxel (ABI-007) for In Stent Restenosis (SNAPIST)
6. Trial of BiDil Added to Standard Therapy in African-American Patients with Heart Failure (A-Heft)
7. Genetic Risk Assessment of Heart Failure in African-Americans (GRAHF Sub-Study)
8. Comparison of Angiomax and Heparin in Coronary Interventions (Replace-2 Trial)
9. Enhanced External Counterpulsation (EECP) in Heart Failure
10. Laser Angioplasty of Restenosed Stents (LARS Study)
11. Sound Wave Inhibition of Neointimal Growth (SWING Study)
12. Safety and Efficacy of BO-653 antioxidant in the prevention of stent restenosis (Prevail Study)
13. Safety and performance of the Safe Steer guidewire system to traverse chronic total coronary occlusions
14. Registry of debris removal with PercuSurge for use in SVG interventions
15. Effects of Brachytherapy with B-emitting liquid Rhenium on stent restenosis in a porcine model
16. Inhibition of stent restenosis with local delivery of CDC2 kinase and PCNA ribozymes in a porcine model
17. Effects of clopidogrel on stent thrombosis and restenosis in a porcine model
18. Comparison of Excimer laser angioplasty and balloon angioplasty in total SFA occlusion (PELA Trial)
19. Evaluation of the Wallstent and the Memotherm Iliac stents for the treatment of Iliac Occlusive Disease
20. Safety and Efficacy of stent-graft system for the treatment of sub-renal AAA
21. Safety and Efficacy of a renal artery stent in treating patients with sub-optimal or failed renal angioplasty

Publications:

1. Rabe K, Cordero H, Heuser RR, Hopkins NL, Sievert H. “Carotid Artery Interventions”.  In Practical Handbook of Advanced Interventional Cardiology, Second edition, chapter 22.  Thach N. Nguyen (Editor), Dayi Hu (Editor), Shigeru, Saito Saito (Editor), Cindy L. Grines (Editor), Igor Palacios (Editor). Futura Publishing Company, Inc.  Publishing date:  October 2003.
2. Cordero H, Heuser RR. “The cardiologist and peripheral intervention”.  In Practical Interventional Cardiology, Second Edition, 349-360.  Ever D, Grech, David R, Ramsdale, Taylor & Francis, Inc.  Publishing date Nov 2001.
3. Cordero H, Warburton KD, Underwood PL, Heuser RR. Initial experience and safety in the treatment of chronic total occlusions with fiberoptic guidance technology:  optical coherent reflectometry.  Catheterization and Cardiovascular Interventions 2001, Oct:54(2):180-7.
4. Cordero H, Gupta N, Underwood PL, Gogts ST, Heuser RR. Intracoronary Autologous Blood to seal a Coronary Perforation.  Herz 2001;26:157-60.
5. Cordero H, Heuser RR. “Carotid Artery Interventions”.  In Practical Handbook of Advanced Interventional Cardiology, 325-350.  Cindy Grines, Shigeru Salto (Editor), Dayl Hu (Editor), Vijay Dave (Editor), Thach N. Nguyen.
6. Futura Publishing Company, Inc. Publishing date:  January 2001.
7. Cordero-Yordan H, Lopez AN, Heuser RR. Carotid Artery Percutaneous Angioplasty and Stenting:  Indications, Technical Approach and Complications. Journal of Interventional Cardiology 1999;12(6):499-504.
8. Cordero-Yordan H, Lopez AN, Heuser RR. Saphenous Graft Intervention.  Journal of Interventional Cardiology 1999;12(6):495-497.
9. Honda H, Makkar RR, Litvack F, Cordero H, Eigler N. Demonstration of Enhanced Stent Side-Branch Access by Geometric-Metallic Synergy with the Paragon stent (submitted).

Abstracts:

1. Cordero H, Underwood PL, Heuser RR. Fiber Optic Guidance Technology in the Treatment of Chronic Total Occlusions:  Initial Experience. (Submitted to TCT 2000).
2. Honda H, Makkar R, Li A, Sebastian M, Madhavan S, Cordero H, Whiting J, Litvack F, Eigler N. Brachytherapy with B-emitting rhenium-188 balloon following stent implantation inhibits restenosis. The American Journal of Cardiology: October 1998:supplement 85.
3. Makkar R, Whiting J, Honda H, Li A, Cordero H, Madhavan S, Litvack F, Eigler N. Inhibition of stent restenosis by B-emitting Re-188 balloon is dose-dependent and injury independent. The American Journal of Cardiology: October 1998:supplements 85.
4. Makkar R, Whiting J, Honda H, Li A, Cordero H, Litvack F, Eigler N. Inhibition of stent restenosis by B-emitting Re-188 Balloon is Dose-dependent and Injury-independent. Circulation 1998;98:I-779
5. Makkar R, Honda H, Li A, Cordero H, Whiting J, Litvack F, Eigler N. Brachytherapy with B-emitting Re-188 balloon following stent implantation inhibits restenosis. Circulation 1998;98:I-778
6. Sebastian M, Honda H, Makkar R, Cordero H, Robbins J, Barber J, Eigler, N, Litvak F. Local delivery of chimeric DNA;RNA ribozymes targeting PCNA with the Cordis Crescendo catheter inhibits in-stent restenosis in a porcine model.  JACC 1999;33(2):834-6, 60A.
7. Hayes S, Dhar S, Cordero H, Cohen I, Berman DS. First pass radionuclide Angiography adds incremental value to adenosine low-level treadmill exercise Tc-99 Sestamibi SPECT for detecting multivessel coronary artery disease.  J Nucl Med 1998;39:102.

Dr. Herbert Cordero-Yordan received both his Bachelor of Science degree and his Doctor of Medicine degree at the University of Puerto Rico. He completed his Internal Medicine residency program at Georgetown University Medical Center (1993-1996). He then moved on to Cedar Sinai Medical Center for a Cardiology Fellowship under the directorship of Dr. Prediman K. Shah (1996-1999). He pursued extra training with a Cardiac and Vascular Interventional Fellowship in Phoenix, Arizona under the directorship of Dr. Richard R. Heuser (1999-2000).

Experience/excellence

Dr. Cordero began practicing cardiology in Miami, Florida back in 2000 with Miami International Cardiology Consultants. He relocated to Las Vegas, Nevada in 2003 where he joined  Cardiovascular Consultants of Nevada and Healthcare Partners Nevada before continuing his present practice at Prime Cardiology of Nevada.

Dr. Navratil has been voted one of the Best Doctors in America from 2003-2017 and Best Doctor by Desert Companion from 2015-2018

Dr. Navratil has taught at the University of Nevada, Reno as a clinical assistant professor of medicine. He now has teaching appointments as an associate professor of medicine at Touro University in Henderson.

In 2001, Dr. Narula was voted by residents at the University of Connecticut to be their best teacher and awarded the University of Connecticut Ralph R. Reinfrank, M.D. Award for Excellence in Teaching. He trained cardiology fellows at the University of Mumbai from 2002-2004. In 2009, he was appointed as Adjunct Assistant professor at Touro University, Nevada. From 2011-2020, he chaired the Cardiac Rhythm Division at Mountainview Hospital in Las Vegas.

Dr. David Navratil received his Bachelor of Science from St. Norbert College in Wisconsin. He then went to the University of Wisconsin-Madison for his Doctor of Medicine. He completed his first internal medicine residency at Keesler Air Force Base in Biloxi, Mississippi and his cardiology fellowship at Lackland Air Force Base in Texas. He completed an electrophysiology fellowship at Sequoia Hospital District in Redwood City, California. During this time, he also completed 500 hours in a nuclear medicine preceptorship at Lackland Air Force Base.

Experience/excellence

Dr. Navratil began his practice as a cardiologist/electrophysiologist and was the Director of Electrophysiology at Wilford Hall USAF Medical Center. After relocating to Nevada, he continued his practice with the Heart Institute of Nevada, Nevada Heart Care, Nevada Cardiovascular Arrythmia Associates, Cardiovascular Consultants of Nevada, and DaVita Healthcare Parners. He is now continuing his practice at Prime Cardiology of Nevada. He has special interests in treatment of cardiac arrythmias, cardiac ablation, removal of pacemakers and defibrillator systems and pharmacologic treatment of cardiac arrythmia.

Publication Citations

Kumar RN, Radhika V, Audige VV, Rané SG, Dhanasekaran N. Proliferation-Specific Genes Activated by Galpha12: A Role for PDGFRalpha and JAK3 in Galpha12-Mediated Cell Proliferation. Cell Biochemistry and Biophysics. 2004 August; 41(1): 63-73.

1. Fischell TA, Attia T, Rané S, Salman W. High-Dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein Iib/IIIa inhibitor use for elective coronary interventions. The Journal of Invasive Cardiology. 2006 Oct; 18(10): 487-91.
2. “Hypokalemia Induced VT Storm with Vitamin B-12 Supplementation”: Was awarded a second prize for this oral presentation at the New England Electrophysiology Society (NEEPS) meeting in April 2012.
3. Rané S, Patton K. Impact of Sex and Ethnicity on Arrhythmic Risk. Curr Cardiol Rep. 2015 Jul;17(7):604.
4. “Incidence of Esophageal Thermal Injury with Cryoballoon and Contact Force Radiofrequency Ablation”: Santosh Rané, Mark Willcox, Jeffrey Ho, Cynthia Ko and Nazem Akoum. Poster presentation at Heart Rhythm Society 2016, San Francisco.
5. “The Vortex of 3D mapping with a Centrifugal Ventricular Assist Device”: Willcox ME, Rané SG, Mahr C, Mokadam N and Akoum N. Poster presentation at Heart Rhythm Society 2016, San Francisco. Manuscript accepted by Europace Journal.

Dr. Santosh Rané has participated in publications and presentations throughout his career. He has advanced expertise in internal medicine, cardiovascular medicine and clinical cardiac electrophysiology.

Additionally, he has procedural competency in many fields.

1. CIED’s including Subcutaneous ICD implantation
2. Atrial Fibrillation ablation- RF and Cryoballoon
3. Complex Atrial arrhythmia ablation
4. Ventricular arrhythmia ablation- Idiopathic and Structural Heart Disease

In August 2020, Dr. Narula was the first doctor in Las Vegas to successfully implant a pacemaker lead to directly pace the left bundle branch. This is a cutting-edge procedure that offers help to patients with weak hearts and congestive heart failure to improve heart function and quality of life.

1. INcreaseOfVAgalTonE in chronic Heart Failure (INOVATE-HF) – A Randomized Study to establish the Safety and Efficacy of CardioFit™ for the Treatment of Subjects with Heart Failure and Left Ventricular Dysfunction (Biocontrol). The purpose of this study is to determine whether the CardioFit™ system is safe and useful for treating patients with heart failure.
2. Patient Surveillance Registry (Medtronic)
   The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
3. Evera MRI™ Clinical Study (Medtronic)
   The purpose of this study is to test the Medtronic Evera MRI implantable cardioverter defibrillator (ICD) system when patients who have this system have an MRI scan. Doing an MRI scan on a person with an Evera MRI ICD is considered an investigational procedure.  However, none of the other study-related procedures or tests are investigational.
4. Evera MRI Continued Access (Medtronic)
   The purpose of this clinical study is to provide access to data collection the Medtronic Evera MRI implantable cardioverter defibrillator (ICD) system and to continue to assess the safety of the system during the FDA review process.
5. Beat-HF Clinical Tria (CVRx)
   The purpose of this study is to evaluate the investigational BAROSTIM NEO implantable device, designed to electrically stimulate the baroreceptors located on one of the carotid arteries in theneck. This may result in improved heart function and reduced heart failure symptoms.

1. SureScan™ Pacing System Post-Approval Study Protocol (Medtronic)
   The purpose of this post-approval study is to collect information over time regarding the long-term performance of the SureScan Pacing system.
2. Attain Performa Attain Performa™ Quadripolar Lead Clinical Study (Medtronic)
   The purpose of this clinical study is to test the safety and effectiveness of the Medtronic Attain Performa quadripolar, left ventricular pacing lead.  The study device and the study lead are investigational.
3. RV Optisure Post Approval Study (St. Jude Medical)
   This is a post market approval study of the long-term performance on subjects who have been either implanted with one of St. Jude Medical’s family of high voltage right ventricular leads within the past 30 days or is having one of St. Jude Medical’s family of high voltage right ventricular leads implanted.
4. Cross X 4 Study Quadripolar CRT-D On Currently Approved Lead SystemS – CROSS X4 Study (Boston Scientific). This is a post-market approval study to evaluate the different ways to program the system to provide therapy. The device and the lead have been approved by the Food and Drug Administration for commercial use and are not considered to be experimental.It is for subjects who will undergo a new CRT-D system implant or a CRT-D system upgrade using a Boston Scientific CRT device which allows for 3 leads to be implanted, one of which is St. Jude Medical Quartet LV lead.
5. Quadripolar Pacing Post Approval Study (St. Jude Medical)
   This is a post-market approval study to assess the safety and efficacy of the Quadripolar CRT-D device system at 5 years in a patient population indicated for cardiac resynchronization therapy.
6. UNTOUCHED: Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low Ejection Fraction (Boston Scientific)
   Post-market approval study with objectives to assess the incidence of shocks in subjects implanted with the EMBLEM S-ICD programmed with a conditional shock zone of 200 beats per minute and a shock zone of 250 beats per minute and have an indication for primary prevention of sudden cardiac death and ejection fraction of less than or equal to 35%, and to assess peri-operative complications.
7. CARDIOMEMS CardioMEMS™ HF System Post Approval Study (St. Jude Medical)
   The objective of this Post Approval Study is to demonstrate that data collected related to the use of the CardioMEMS HF System in a commercial setting are comparable with data collected in a controlled clinical trial. This study will give patients, doctors, the sponsor, and the FDA valuable information on the safety, effectiveness and reliability of the Cardiomems HF system.
8. aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation. (SentreHEART, Inc.) This study is a prospective, multicenter, randomized (2:1) controlled study to evaluate the safety and effectiveness of the LARIAT System to percutaneously isolate and ligate the Left Atrial Appendage from the left atrium as an adjunct to planned pulmonary vein isolation (PVI) catheter ablation in the treatment of subjects with symptomatic persistent or longstanding persistent atrial fibrillation.

Dr. Narula, in collaboration with Dr. Jeffrey Levisman, Dr. Thomas Lambert and Dr. Alfred Danielian, started the Watchman program at Mountainview Hospital. The Watchman device is used to reduce the risk of stroke in patients with atrial fibrillation without the bleeding risks associated with the use of blood thinners. In 2019, Mountainview Hospital completed 100 implants and the team at Mountainview has the most experience in Las Vegas.